Dr. Panzara is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
Wave Life Sciences
733 Concord Ave
Cambridge, MA 02138Phone+1 617-949-2977
Education & Training
Brigham and Women's Hospital/Massachusetts General Hospital/Harvard Medical SchoolResidency, Neurology, 1995 - 1998
Stanford University School of MedicineClass of 1994
Harvard School of Public HealthMasters in Public Health
Certifications & Licensure
MA State Medical License 1997 - 2026- American Board of Psychiatry and Neurology Neurology
Clinical Trials
- Safety and Efficacy of Natalizumab in the Treatment of Multiple Sclerosis Start of enrollment: 2001 Nov 01
- Safety and Efficacy of Natalizumab in Combination With Avonex in the Treatment of Multiple Sclerosis Start of enrollment: 2002 Jan 01
- Open-Label Natalizumab Safety Extension Study Start of enrollment: 2003 Dec 01
- Join now to see all
Publications & Presentations
PubMed
- 408 citationsRituximab in relapsing-remitting multiple sclerosis: a 72-week, open-label, phase I trial.Amit Bar-Or, Peter A. Calabresi, Douglas L. Arnold, Clyde E. Markowitz, Stuart Shafer
Annals of Neurology. 2008-03-01 - 16 citationsDiffusion‐Weighted Magnetic Resonance Imaging Abnormalities in Bartonella EncephalopathyAneesh B. Singhal, Michael C. Newstein, Ronald F. Budzik, Jang-Ho Cha, Guy Rordorf
Journal of Neuroimaging. 2003-01-01 - 1597 citationsB-cell depletion with rituximab in relapsing-remitting multiple sclerosis.Stephen L. Hauser, Emmanuelle Waubant, Douglas L. Arnold, Timothy Vollmer, Jack P. Antel
The New England Journal of Medicine. 2008-02-14
Press Mentions
Hope in the Wake of Recent Failures in Huntington’s DiseaseAugust 17th, 2021- Wave Life Sciences Appoints Dr. Ken Rhodes as Senior Vice President, Therapeutics DiscoveryMay 18th, 2020
Is It over for This Huntington’s Disease Clinical Trial?December 30th, 2019- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
